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Predisposition to psoriasis is known to be affected by genetic variation in HLA-C, IL12B and IL23R, but other
genetic risk factors also exist. We recently reported three psoriasis-associated single nucleotide polymor-
phisms (SNPs) in the 5q31 locus, a region of high linkage disequilibrium laden with inﬂammatory pathway
genes. The aim of this study was to assess whether other variants in the 5q31 region are causal to these
SNPs or make independent contributions to psoriasis risk by genotyping a comprehensive set of tagging
SNPs in a 725 kb region bounded by IL3 and IL4 and testing for disease association. Ninety SNPs, capturing
86.4% of the genetic diversity, were tested in one case–control sample set (467 cases/460 controls) and sig-
niﬁcant markers (Pallelic < 0.05) (n 5 9) were then tested in two other sample sets (981 cases/925 controls). All
nine SNPs were signiﬁcant in a meta-analysis of the combined sample sets. Pair-wise conditional association
tests showed rs1800925, an intergenic SNP located just upstream of IL13 (Mantel–Haenszel Pcombined 5 1.5 3
10
24,O R5 0.77 [0.67–0.88]), could account for observed signiﬁcant association of all but one other SNP,
rs11568506 in SLC22A4 [Mantel–Haenszel Pcombined 5 0.043, OR 5 0.68 (0.47–0.99)]. Haplotype analysis of
these two SNPs showed increased signiﬁcance for the two common haplotypes (rs11568506–rs1800925:
GC, Pcombined 5 5.67 3 10
26,O R 5 1.37; GT, Pcombined 5 6.01 3 10
25,O R 5 0.75; global haplotype
P 5 8.93 3 10
25). Several 5q31-region SNPs strongly associated with Crohn’s disease (CD) in the recent
WTCCC study were not signiﬁcant in the psoriasis sample sets tested here. These results identify the
most signiﬁcant 5q31 risk variants for psoriasis and suggest that distinct 5q31 variants contribute to CD
and psoriasis risk.
INTRODUCTION
Genome wide association (GWA) studies have proven power-
ful in identifying single nucleotide polymorphisms (SNPs)
that are signiﬁcantly associated with common, multi-factorial
diseases (1–3). However, given the nature of these scans,
the identiﬁed markers may not be causal but rather in
linkage disequilibrium (LD) with the true causative variants
located elsewhere, possibly in a neighboring, unrelated gene.
Furthermore, there may be multiple variants in a region that,
independently or together, contribute to disease risk (4,5).
Consequently, comprehensive follow-up ﬁne mapping of
signiﬁcant GWA markers, which incorporates the rich
genetic information revealed by the HapMap project (6), is
required to narrow the region of interest and identify true
causal variant(s).
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Advance Access published on July 9, 2008Psoriasis is a common, chronic inﬂammatory skin disease
that can affect individuals of all ages with the majority
manifesting clinical symptoms before the age of 40 years
(7). Susceptibility to psoriasis is strongly inﬂuenced by
genetic factors, independently or interacting with each other,
and may be initiated or exacerbated by environmental
factors such as infection. Haplotypes carrying the HLA-
Cw 0602 allele confer the strongest genetic effect in whites,
particularly among early onset cases (8,9). More recently,
association of psoriasis with SNPs in IL12B and IL23R has
been identiﬁed (2,10) and independently conﬁrmed in other
case–control studies (11–13). Thus, a total of three psoriasis
risk loci have been established with convincing statistical
evidence.
These genetic variations, however, do not explain the total-
ity of psoriasis risk, suggesting other genetic risk factors exist.
Indeed, linkage studies have provided evidence suggesting
other genomic loci are signiﬁcantly associated with this
disease (14). In addition, numerous putative risk factors have
been reported, often with substantial appeal as strong biologi-
cal and/or positional candidates (reviewed in 15,16). Recent
additions to the growing list of potential genetic risk factors
for psoriasis include variation in genomic copy number of
ß-defensin (17) and SNPs and/or haplotypes in ADAM33
(18), IL15 (19) and CDKAL1 (20).
WerecentlyreportedthatthreeSNPs(rs1800925,rs20541and
rs848) in the IL13-region at the 30-end of the 5q31 cytokine gene
cluster were associated with psoriasis in a large, multi-tiered,
genetic association study (21). The 5q31 genomic region con-
tains a cluster of cytokine and immune-related genes, including
interleukin (IL) genes IL3, IL4, IL5 and IL13; interferon regulat-
o r yf a c t o r - 1( IRF-1); colony-stimulating factor-2 (CSF2)a n d
T-celltranscriptionfactor-7(TCF7),allexcellentbiologicalcan-
didategenes.Thisregionshowsextendedmarker–markercorre-
lation; for example, examination of the CEU HapMap dataset
(www.hapmap.org) reveals that a number of markers within
the 100 kb interval immediately upstream of IL13 are in rela-
tively strong LD (r
2 . 0.5) with one of the signiﬁcant IL13
SNPs, rs20541. Numerous other markers extending as far as
1 Mb upstream of IL13 also show moderate LD with rs20541
(r
2 . 0.2).Therefore,tomorepreciselydeﬁnethecausalvariants
in the 5q31 region, we carried out a comprehensive analysis of
thegenetic variation inthisregion usingthree large, independent
sample sets, totaling 1448 cases and 1385 controls, and report
ﬁndings from association tests of the markers with psoriasis risk.
RESULTS
Single marker analysis identiﬁes multiple SNPs
associated with psoriasis
Examination of the 5q31 LD structure in the CEU HapMap
Phase II dataset led us to focus our ﬁne mapping on a 725 kb
region that delimits the entire cytokine cluster, extending
from 50 kb upstream of IL3 to 50 kb downstream of IL4.
Ninety ﬁne mapping SNPs, primarily selected as tagging
markers (see Materials and methods), were genotyped in 467
cases and 460 controls (sample set 1) (Fig. 1A). In addition to
the three original IL13-region SNPs (21), allelic association
tests of the 90 new SNPs identiﬁed nine additional markers
signiﬁcantly associated with psoriasis (Pallelic , 0.05, Fig. 1A
and Supplementary Material, Table S1) in a 370 kb region
extending from SLC22A4 to KIF3A and including IRF1, IL5,
IL13 and IL4. These nine SNPs were then genotyped in two
other case–control sample sets (sample set 2: 498 cases/498
controls; sample set 3: 483 cases/427 controls) and although
the signiﬁcance of these nine markers varied in the two
follow-up sample sets (Fig. 1A and Supplementary Material,
Table S2), all nine were signiﬁcant in a combined analysis of
the three sample sets (Mantel–Haenszel Pcombined , 0.05,
Table 1 and Supplementary Material, Table S2). Breslow–
Day tests provided no evidence for heterogeneity of effect
across sample sets except for one marker, rs11568506 [odds
ratio (OR) homogeneity: Prs11568506 ¼ 0.032; P . 0.05 for all
other markers]. Based on the Pcomb-values, none of the nine
new markers were more signiﬁcant than rs1800925 (Mantel–
Haenszel Pcombined ¼ 0.00015), the most signiﬁcant marker
identiﬁed in our original report (21), although some were com-
parable (e.g. P ¼ 0.00022 for the IL4 marker rs2227282). ORs
conferred by these variants were all modest (Table 1 and Sup-
plementary Material, Table S2).
Conditional analysis reveals two independent SNPs
ToteaseapartassociationsignalsfrompatternsofLDanddeter-
mine which of these 12 signiﬁcant SNPs were independently
associated with psoriasis risk, we performed pair-wise
genotype-conditioned analyses. Using the combined datasets,
we calculated a summary statistic for each pair of SNPs using
the genotypes of one marker conditioned on another marker,
and evaluated the signiﬁcance of each result using a permu-
tation test (10,000 permutations) (Table 2). This approach is
similartothe haplotypemethod(22) andhasbeen described pre-
viously(2).Notsurprisingly,thesigniﬁcantassociationofvarious
SNPs with psoriasis disappeared upon conditioning on other
markers. Most notably, the signiﬁcance of all other markers
except rs11568506 (in SLC22A4; P ¼ 0.0105) was abolished
upon conditioning on rs1800925. Conversely, association of
rs1800925 remained strong (P ¼ 0.0002) upon conditioning on
rs11568506. Together these data suggest that rs11568506 and
rs1800925 make independent contributions to psoriasis risk.
The genotype correlation between rs11568506 and rs1800925
is very low (r
2 ¼ 0.006), whereas that between rs1800925 and
the other 10 SNPs varied from 0.016 to 0.801 (Supplementary
Material, Table S3).
Next we assessed whether SNPs in high LD with rs1800925
could be more signiﬁcantly associated with disease. Genotype
data were retrieved from the HapMap CEU dataset (release
no. 22, phase II April 07), covering 1 Mb on each side of the
IL13 gene, and the correlation (as determined by r
2 values)
between rs1800925 and all 1559 SNPs was calculated. A total
of 32 markers, including ﬁve SNPs in putative transcription
factor binding sites but no cSNPs, were highly correlated with
rs1800925 (r
2 . 0.8) (Supplementary Material, Table S4), 30
of which were in absolute LD (r
2 ¼ 1) with one another. One
of these 30 markers, rs2897443 (r
2 with rs1800925 ¼ 0.897)
had been genotyped in all three psoriasis sample sets (Sup-
plementary Material, Table S2) and was nearly 10-fold less sig-
niﬁcant than rs1800925 (Prs2897443 ¼ 0.001 versus Prs1800925 ¼
0.00015). Inaddition,rs2897443 was no longer signiﬁcant after
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remained signiﬁcant after conditioning on rs2897443 (P ¼
0.0423). The remaining two markers (rs2706370 and
rs12187537) were not genotyped in our study; however, they
were more highly correlated with rs2897443 (r
2 ¼ 0.94) than
withrs1800925(r
2 ¼ 0.829and0.817,respectively)suggesting
their association with psoriasis is most likely less signiﬁcant
than rs1800925. All together, these data indicate that there is
no evidence that any of the HapMap SNPs are more signiﬁ-
cantly associated with psoriasis than rs1800925.
Given that two markers, rs11568506 and rs1800925,
show independent association with psoriasis, we carried out
haplotype analyses using both markers in each of the three
individual sample sets and in a combined analysis of all
three sample sets. Although it is difﬁcult to determine
whether the two independent markers reside in the same LD
block (Fig. 1B), the number of double heterozygotes was
small (7 cases and 16 controls out of 2800 samples; Sup-
plementary Material, Table S5); therefore, phase could be
unambiguously established in 99.2% of all individuals.
Three haplotypes were observed, with the fourth being rela-
tively rare (,0.001 in cases or controls) due to the low fre-
quency of rs11568506. The two common haplotypes were
signiﬁcantly associated with psoriasis in two of the three
Figure 1. (A) P-values of SNPs tested in the three sample sets individually (SS1, SS2 and SS3) and combined (Meta). A total of 93 SNPs were tested in sample
set 1; 12 SNPs were tested in sample sets 2 and 3. rs1800925, rs20541 and rs848, which we previously reported to be associated with psoriasis (21), were tested in
all three sample sets. A gene map is shown at the bottom, based on the NCBI b36 genome assembly. (B) Inter-marker LD of the 93 markers in sample set 1. D’
values are shown in the top right triangle, and r
2 values are in the bottom triangle. The D’ and r
2 values were calculated using both cases and controls from
sample set 1.
2980 Human Molecular Genetics, 2008, Vol. 17, No. 19sample sets; although they were not signiﬁcant in sample set 2,
the ORs were in the same direction as in the other two sample
sets (Table 3). In a meta-analysis, both common haplotypes
were signiﬁcantly associated with psoriasis, and signiﬁcance
of the most common haplotype, GC, was markedly higher
than any single SNP (P ¼ 5.67   10
26 for the haplotype
versus 1.5   10
24 for rs1800925). The observed effect sizes
in the combined analysis of all sample sets were 1.37 for the
predisposing GC (rs11568506–rs1800925) haplotype (fre-
quency: 0.827 in cases versus 0.777 in controls) and 0.75 for
the protective GT haplotype (frequency: 0.156 in cases
0.198 in controls).
Distinct SNPs are associated with psoriasis and Crohn’s
disease (CD)
Previous studies have identiﬁed linkage of the 5q31 locus and/or
association of speciﬁc variants in this region with several other
diseases, including CD and asthma/allergic disorders (23–25).
Because psoriasis and CD may share a common genetic etiology
[psoriasis is approximately ﬁve times more common in CD
patients than in controls (26) and the same IL23R missense
SNP is associated with both diseases (1,2,11–13)], we tested
our psoriasis sample sets for 5q31 SNPs showing strong
association with CD (3). Of the 90 ﬁne-mapping markers
described above, ﬁve, strongly associated with CD in the
WTCCC study (rs2285673, rs4540166, rs2522057, rs6596075
and rs10077785; all with P , 5   10
25 in 2000 cases and
3000 controls (3)], were genotyped in our three psoriasis
sample sets. None were signiﬁcant in the individual sample
sets (all P . 0.05) (data not shown), although one SNP,
rs2522057, was signiﬁcantly associated with psoriasis in a
meta-analyses of all three sample sets combined (P ¼ 0.022)
(Table 4). The pair-wise conditional association test, however,
showed that this signiﬁcant association could be accounted for
by the IL13 marker, rs1800925 (P ¼ 0.60 for rs2522057 con-
ditioned upon rs1800925, whereas rs1800925 remained signiﬁ-
cant when conditioned upon rs2522057, P ¼ 0.017).
Assuming a type I error rate of 0.05 and the population allele
frequency observed in the WTCCC study, our combined analy-
sis had 90% power to detect an allelic effect equal to an OR of
1.25, similar to the reported OR of 1.37 for rs6596075, which
tags the 5q31 CD risk haplotype. Thus, variants contributing
to CD risk in this genomic region, which map 50 of the
psoriasis-associated SNPs near the LOC441108-region, do not
make an independent contribution to the etiology of psoriasis
inoursample sets. Inaddition, althoughneither ofthetwo inde-
pendent psoriasis markers, rs1800925 and rs11568506, was
tested in the WTCCC’s CD sample set, four other markers in
high LD with rs1800925 (r
2 ¼ 0.9 for all) were tested and
were not signiﬁcant in their study. Therefore, association with
CD and psoriasis in this region appears to be explained by
different variants.
DISCUSSION
Our analysis of the 5q31 cytokine cluster reveals that multiple
SNPs are signiﬁcantly associated with psoriasis risk; however,
incorporating LD into our analysis revealed two independent,
psoriasis-associated SNPs: rs1800925 located 50 of IL13 and
rs11568506, an intronic SNP in SLC22A4,a l s ok n o w na s
organic cation transporter 1 (OCTN1). The observed signiﬁ-
cance was only marginal for the SLC22A4 marker (Mantel–
Haenszel Pcombined ¼ 0.043). However, combining the genotype
information for this marker with the more frequent IL13 marker,
which is also more signiﬁcant (Mantel–Haenszel Pcombined ¼
0.00015), resulted in two common psoriasis-associated haplo-
types that were both highly signiﬁcant. In particular, the
major risk haplotype, with a control allele frequency of 0.777
increasing to 0.827 in cases, showed more pronounced associ-
ation with psoriasis (Pcombined ¼ 5.67   10
26,O R ¼ 1.37)
than any of the individual markers.
The biological interpretation of this observation (i.e. vari-
ants in two linked genes) is not straight-forward; however,
both SLC22A4 and IL13 are putative genetic risk factors for
other autoimmune or autoinﬂammatory disorders. Speciﬁcally,
two-locus functional polymorphisms (haplotypes) in SLC22A4
and the adjacent SLC22A5 genes have been reported to be
associated with CD (27), although deﬁnitive causal variants
remain to be determined (28,29). Variation in IL13, which
encodes an immunoregulatory cytokine produced by activated
T helper 2-type (Th2) cells, has been most prominently associ-
ated with asthma (23), as well as atopic dermatitis (30). Thus,
both genes have strong a priori plausibility as risk factors of
psoriasis, particularly as the evidence for shared risk variants
across multiple autoimmune disorders increases (31,32).
Table 1. Association analysis of the two independent, psoriasis-associated SNPs in the three sample sets combined
a
SNP ID Gene Allele/Genotype Cases, n (%) Controls, n (%) OR (95% CI) P-value
rs11568506 SLC22A4 A 50 (0.017) 69 (0.025) 0.68 (0.47–0.99) 0.043
G 2820 (0.983) 2677 (0.975) 1.00 (reference)
AA 2 (0.0014) 0 (0) NC
b 0.022
AG 46 (0.032) 69 (0.050) 0.63 (0.43–0.92)
GG 1387 (0.0967) 1304 (0.950) 1.00 (reference)
rs1800925 IL13 T 453 (0.158) 540 (0.196) 0.77 (0.67–0.88) 0.00015
C 2417 (0.842) 2210 (0.804) 1.00 (reference)
TT 36 (0.025) 56 (0.041) 0.56 (0.37–0.86) 0.00081
TC 381 (0.266) 428 (0.311) 0.78 (0.66–0.92)
CC 1018 (0.709) 891 (0.648) 1.00 (reference)
aData for the 10 other signiﬁcant SNPs are presented in Supplementary Material, Table S2.
bNot calculated.
Human Molecular Genetics, 2008, Vol. 17, No. 19 2981Alternatively, rs11568506 might be in high LD with another,
untested SNP closer to IL13 so that the ‘independent’ effect
could be explained by another variant within or near IL13.
Further experimentation should help determine whether one
or both of these genes play a role in the disease process.
The two identiﬁed SNPs are located in an intron of
SLC22A4 and near the 50-end of IL13, respectively, with no
predictive functional signiﬁcance based on current SNP anno-
tation, although rs11568506 is 43 bp from a POU2F1 tran-
scription factor binding site, which exhibits a high degree of
conservation across multiple placental mammals. In the
absence of a validated role for these SNPs in gene regulation,
and the presence of several other excellent biological candi-
date genes within this region as well as critical regulatory
elements (33), it is tempting to speculate that untested,
causal genetic variant(s) may lie on the haplotype deﬁned by
rs11568506 and rs1800925. Although our comprehensive,
HapMap-based analysis of the variation in this region pro-
vided no evidence for such a marker, we were unable to
develop assays for tagging SNPS covering 13.6% of the vari-
ation. In addition, SNPs not available in the HapMap, such as
our most signiﬁcant marker, rs1800925, may explain these
results. Similarly, other genetic variants (insertions, deletions,
etc.) which have been implicated in the etiology of various
complex diseases, including psoriasis (17,34), may be respon-
sible for modulating disease susceptibility.
The recent identiﬁcation of IL23R variants associated with
both psoriasis and CD solidiﬁes the notion that genetic etiol-
ogy may overlap between these two diseases (1,2). However,
even though 5q31 linkage signals have been observed for
both diseases (35–37), our data suggest that distinct markers
within this region contribute to CD and psoriasis risk.
Several previously reported CD-associated markers in the
5q31 region, including one that tags a risk haplotype
(rs6596075), were not signiﬁcant in our psoriasis sample sets
despite having sufﬁcient power to detect an effect size
similar to that observed in the CD study (3). In addition, the
modest association of rs2522057 with psoriasis in the com-
bined analysis of our sample sets could be explained by LD
with the most signiﬁcant marker, rs1800925. This observation
is consistent with a recent report that failed to detect a signiﬁ-
cant association between psoriasis and three other
CD-associated SNPs in SLC22A4 and SLC22A5 (38). It is
possible that the lack of association may be partly confounded
by the fact that the actual causal CD variants have not been
tested. However, judging from the signiﬁcance level observed
in the WTCCC study (3), and unless there are signiﬁcant
differences in the LD structure between their sample sets
and ours (which is unlikely), we favor the interpretation that
susceptibility to psoriasis and CD are affected by distinct
genetic variants at this locus or the same variants but with
different effect sizes.
Finally, it is possible that we may not have the power to
detect independent effects in our sample sets. Thus, although
the signiﬁcance of all other markers except rs11568506 can
be accounted for by rs1800925, we cannot exclude the possi-
bility that other markers, particularly the stronger ones in IL13
and IL4, make additional, independent contributions to disease
risk. In addition, the possibility that our current ﬁnding is false
positive cannot be completely discounted, since the observed
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2982 Human Molecular Genetics, 2008, Vol. 17, No. 19signiﬁcance will not survive multiple testing corrections if all
markers tested in our previous genome-wide scan and in this
study are considered—which is generally deemed
conservative. However, in an unpublished GWA study of
1400 white North American cases and 1400 white North
American controls, two of our original IL13-associated
SNPs, rs20541 and rs848, exhibit very strong evidence for
association (Abecasis, Bowcock, Krueger and Elder, personal
communication). These data suggest markers in the 5q31
region are true psoriasis risk markers; validation in other
sample sets of similar characteristics is warranted to bring
further deﬁnition to the causal variant(s).
MATERIALS AND METHODS
Clinical samples
Three sample sets of psoriasis cases and unaffected controls
were assembled for this study. Detailed demographics and
diagnostic/enrollment criteria have been described in a
previous publication (2). Brieﬂy, all individuals are North
American whites of European descent and were 18 years or
older when they contributed their samples (sample set 1: 467
cases/460 controls; sample set 2: 498 cases/498 controls;
sample set 3: 483 cases/427 controls). Informed written
consent was obtained from all participants, and all protocols
were approved by national and/or local institutional review
boards.
Selection of tagging SNPs and overall study design
To comprehensively yet efﬁciently investigate the 5q31
region, we ran the MIT tagger program (http://www.broad.
mit.edu/mpg/tagger/server.html) (39) with the CEU HapMap
phase II dataset [the landmarks were set at chr5:1313731
31...132097638 bp (NCBI Build 36); minimal allele fre-
quency was set at 0.02; r
2 threshold was set at 0.8; and
tagging mode was set at pair-wise]. A total of 103 tagging
SNPs (including the previously tested IL13 marker rs20541)
are required to capture the SNP diversity (610 polymorphic
sites) within this 725 kb region. Assay designs were attempted
on the default tagging markers, and when not feasible, on an
alternative marker within the tagging group. We referenced
the WTCCC study to preferentially select markers that were
signiﬁcantly associated with CD as tagging markers. We were
able to develop assays for 90 of these tagging SNPs (excluding
the assay already available for rs20541). In addition, assays for
two SNPs in predicted transcription factor binding sites
(rs381870 and rs4540166) were developed.
The above 92 SNPs were genotyped in one of the three
psoriasis case–control sample sets (sample set 1; 467 cases/
460 controls). Genotyping data for 90 markers, including 88
tagging markers (equivalent to 86.4% coverage for all
tagging markers), passed quality control and were subjected
to further analysis. Hardy–Weinberg equilibrium tests ident-
iﬁed six markers in controls and two others in cases with
P , 0.05 (Supplementary Material, Table S1). However,
Table 3. Haplotype association tests
Sample set Haplotype
a (rs11568506/rs1800925) Cases, n (%) Controls, n (%) Phaplotype Global P OR
SS1 GC 771 (0.844) 713 (0.787) 0.0019 0.0028 1.46
GT 131 (0.143) 167 (0.184) 0.018 0.74
AC 12 (0.013) 26 (0.029) 0.019 0.45
SS2 GC 796 (0.807) 765 (0.781) 0.13 0.11 1.18
GT 168 (0.170) 199 (0.203) 0.052 0.81
AC 22 (0.022) 15 (0.015) 0.36 1.48
SS3 GC 799 (0.830) 651 (0.764) 0.00091 0.0028 1.51
GT 147 (0.153) 175 (0.205) 0.0069 0.70
AC 13 (0.014) 26 (0.031) 0.031 0.45
All
b GC 2366 (0.827) 2128 (0.777) 5.67E206 8.93E205 1.37
GT 446 (0.156) 542 (0.198) 6.01E205 0.75
AC 47 (0.017) 68 (0.025) 0.053 0.66
aFrequency of AT haplotype is ,0.001 in both cases or controls.
bHaplotype counts were estimated and may vary slightly from the sum of the three individual sample sets.
Table 4. Association of putative CD SNPs with psoriasis
Marker Chr Position (bp) Gene Psoriasis (SS1þSS2þSS3) CD (WTCCC)
a
Allele frequency Allele frequency
Case Control Pallelic OR (95% CI) Case Control Pallelic OR (95% CI)
rs6596075 5 131 770 127 0.162 0.164 0.82 0.98 (0.85–1.14) 0.127 0.166 5.40E207 0.73 (0.65–0.83)
rs2285673 5 131 783 868 LOC441108 0.226 0.235 0.43 0.95 (0.84–1.08) 0.212 0.252 1.50E205 0.80 (0.73–0.89)
rs4540166 5 131 807 756 LOC441108 0.205 0.212 0.52 0.96 (0.84–1.09) 0.189 0.228 8.98E206 0.79 (0.71–0.88)
rs10077785 5 131 829 057 0.209 0.218 0.45 0.95 (0.84–1.09) 0.192 0.234 1.81E206 0.78 (0.70–0.86)
rs2522057 5 131 829 846 0.444 0.414 0.022 1.13 (1.02–1.26) 0.478 0.422 1.01E207 1.29 (1.20–1.33)
aData are from WTCCC (3).
Human Molecular Genetics, 2008, Vol. 17, No. 19 2983analysis of the data showed no apparent error in genotype
assignment for these markers, thus they were included in the
association tests. As predicted, inter-marker LD between the
genotyped markers was low in our samples (Fig. 1B). Signiﬁ-
cant SNPs (P , 0.05) were then genotyped in two other case–
control sample sets [sample set 2 (498 cases/498 controls) and
sample set 3 (483 cases/424 controls)].
Genotyping
Genotyping was carried out by the method of real-time, allele-
speciﬁc PCR withprimers designedandvalidated in-house (40)
(primer information is available upon request). Genotype calls
of cases and controls, randomly arrayed onto genotyping
plates, were made using an automated algorithm and were
subjected to manual examination without knowledge of case–
control status, prior to statistical analysis. Genotyping accuracy
has been consistently better than 99% (2,41).
Statistical analysis
Hardy–Weinberg equilibrium was examined by an exact test.
Allelic association of SNPs with psoriasis risk was determined
by the x
2 test in individual sample sets and by meta-analysis
using ﬁxed effects of Mantel–Haenszel methods to combine
ORs across the sample sets. Marker conditional association
tests were done using an approach similar to the haplotype
method (22) as previously described (2). In brief, cases and
controls were partitioned on the basis of genotypes at one
SNP, and counts at an interrogated SNP were subjected to
analysis, where statistical signiﬁcance was assessed by a per-
mutation method (10 000 permutations). The marker–marker
LD measurements, D’ and r
2 were calculated using LDMax
(www.sph.umich.edu/csg/abecasis/GOLD/docs/ldmax.html).
Haplotypes were estimated and tested for association with
disease status using a score test with haplotypes coded in an
additive fashion (42). Power calculations were done using
the PS:Power and Sample Size Calculation Program, obtained
from the Department of Biostatistics, Vanderbilt University
website (http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/
PowerSampleSize).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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